Journal Article

Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients

Steele, Jeffrey, Molina, Kyle C., Carlson, Nichole E., Aggarwal, Neil R., Ong, Toan C., Peers, Jennifer L., Bennett, Tellen D., Mayer, David A., Douin, David J., Beaty, Laurel E., Wogu, Adane F., Ginde, Adit A., Wynia, Matthew K., Russell, Seth

2022

Overview

Background Neutralizing monoclonal antibodies (mAbs) are highly effective in reducing hospitalization and mortality among early symptomatic COVID-19 patients in clinical trials and real-world data. While resistance to some mAbs has since emerged among new variants, characteristics associated with treatment failure of mAbs remain unknown. Methods This multicenter, observational cohort study included patients with COVID-19 who received mAb treatment between November 20, 2020, and December 9, 2021. We utilized electronic health records from a statewide health system plus state-level vaccine and mortality data. The primary outcome was mAb treatment failure, defined as hospitalization or death within 28 days of a positive SARS-CoV-2 test. Results COVID-19 mAb was administered to 7406 patients. Hospitalization within 28 days of positive SARS-CoV-2 test occurred in 258 (3.5%) of all patients who received mAb treatment. Ten patients (0.1%) died within 28 days, and all but one were hospitalized prior to death. Characteristics associated with treatment failure included having two or more comorbidities excluding obesity and immunocompromised status (adjusted odds ratio [OR] 3.71, 95% confidence interval [CI] 2.52–5.56), lack of SARS-CoV-2 vaccination (OR 2.73, 95% CI 2.01–3.77), non-Hispanic black race/ethnicity (OR 2.21, 95% CI 1.20–3.82), obesity (OR 1.79, 95% CI 1.36–2.34), one comorbidity (OR 1.68, 95% CI 1.11–2.57), age ≥ 65 years (OR 1.62, 95% CI 1.13–2.35), and male sex (OR 1.56, 95% CI 1.21–2.02). Immunocompromised status (none, mild, or moderate/severe), pandemic phase, and type of mAb received were not associated with treatment failure (all p > 0.05). Conclusions Comorbidities, lack of prior SARS-CoV-2 vaccination, non-Hispanic black race/ethnicity, obesity, age ≥ 65 years, and male sex are associated with treatment failure of mAbs.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Aged / Antibodies, Monoclonal - therapeutic use / Antibodies, Neutralizing / Clinical trials / Comorbidity / Coronaviruses / COVID-19 / COVID-19 Vaccines / Death / Electronic health records / Electronic medical records / Failure / HIV / Hospitalization / Human immunodeficiency virus / Humans / Infectious Diseases / Internal Medicine / Male / Males / Medical Microbiology / Medicine / Medicine & Public Health / Minority & ethnic groups / Monoclonal antibodies / Mortality / Neutralizing / Obesity / Observational studies / Outpatients / Pandemics / Parasitology / Patients / Race / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Sex / Treatment Failure / Tropical Medicine / Vaccination / Vaccines